Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX3 plus bevacizumab in metastatic colorectal cancer
2024-515908-39-00Phase 2Authorised
- Sponsor
- Centre Georges-François Leclerc
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of folinic acid + 5-fluorouracil + oxaliplatin + irinotecan and bevacizumab in metastatic colon cancer (mCRC), sponsored by Centre Georges-François Leclerc. Planned start Aug 2024; status: authorised.
02
Drugs
folinic acid + 5-fluorouracil + oxaliplatin + irinotecanbevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-515908-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515908-39-00.